Сравнение на методи

	Анализ на Schild	Анализ на изоболограми	Кинетика на Михаелис-Ментен	Популационно фармакодинамично моделиране
Област	Фармакология	Фармакология	Фармакология	Фармакология
Семейство	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
Година на възникване	1947	1926	1913	1992
Създател	Henry Schild	Salvatore Loewe	Leonor Michaelis and Maud Menten	Lewis Sheiner and Stephen Roush
Тип	antagonism quantification	synergy quantification	mechanistic model	dose-response modeling
Основополагащ източник	Schild, H. O. (1947). pA, a new scale for the measurement of drug antagonism. Journal of Physiology, 106(3), 337-357.	Loewe, S. (1926). Die Mischtoxizität. Zeitschrift für Experimentelle Pathologie und Therapie, 24, 315-334.	Michaelis, L., & Menten, M. L. (1913). Die Kinetik der Invertinwirkung. Biochemische Zeitschrift, 49, 333-369.	Dahlström, B., & Nyberg, L. (1993). Population pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics, 24(1), 45-57.
Други названия	Schild plot, pA2	isobol, combination index, synergy testing	MM kinetics, Michaelis constant, Vmax	PopPD, population PD, hierarchical PD modeling
Свързани	3	3	2	3
Резюме	Schild analysis is a quantitative method for characterizing competitive receptor antagonism developed by Henry Schild in 1947. It uses dose-response curves in the presence and absence of antagonist to estimate the antagonist affinity constant (pA2), enabling standardized comparison of antagonist potency across drugs and experimental systems.	Isobologram analysis is a graphical and quantitative method for detecting and classifying drug interactions, developed by Salvatore Loewe in 1926. It uses dose-response data from two drugs applied individually and in combination to determine whether their interaction is additive, synergistic, or antagonistic.	Michaelis-Menten kinetics describes the rate of enzyme-catalyzed reactions as a function of substrate concentration. Developed by Leonor Michaelis and Maud Menten in 1913, this foundational framework models enzyme catalysis through the rapid-equilibrium approximation and enables prediction of drug metabolism rates in pharmacokinetics.	Population pharmacodynamic (PopPD) modeling integrates pharmacokinetics with individual dose-response relationships across patient populations to characterize drug efficacy and tolerability. Pioneered by Lewis Sheiner and colleagues, PopPD accounts for inter-individual variability in drug effects and enables rational dose optimization and response prediction.